Skip to main content
. 2024 Sep 16;54(12):2451008. doi: 10.1002/eji.202451008

Figure 3.

Figure 3

Schematic representation of the different nanoparticles used to modify NK‐92 and primary NK cells and their limitations and desired effects. Created with BioRender.